Contact:
sales@biotechnologyforums.com to feature here

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Potential Mechanism to Refold Proteins in Neurological Disorders
#1
Many neurological diseases are caused by misfolded proteins in the brain and along the nervous system. These include Charcot-Marie-Tooth disease, Parkinson’s disease, multiple sclerosis, and Alzheimer’s disease. The misfolfded proteins seem to cause damage to the nervous system and prevent proper functioning of the brain and other parts of the nervous system. These diseases are not reversible, and there are no available treatments to help properly fold the proteins after disease has begun.

Charcot-Marie-Tooth (CMT) is a group of diseases that affect the peripheral nervous system in which the myelin sheaths surrounding the nerve cells are not properly formed. Myelin is a fatty material that is produced by a type of cell called Schwann cells. The myelin acts to insulate the nerve cells, allowing electrical impulses to quickly and easily be conducted throughout the body. Breakdown of the myelin sheath due to CMT results in a decreased ability of the nerve to transmit signals, and leads to degeneration of the nerve. The muscle cell activated by the nerve becomes weakened and atrophied due to lack of use, and this is a hallmark of CMT. CMT is one of the most common inherited neurological disorders, affecting about one in every twenty five hundred people in the United States. CMT is a progressive neuropathy, which means that the condition continues to worsen over time. Although CMT is not fatal in and of itself, it can cause severe effects, limiting mobility and decreasing quality of life.

A common mutation associated with certain types ofCMT is in a protein called P0. P0 seems to act as a molecular glue that holds the myelin around the neuron. If the protein is mutated, then the myelin is not properly attached to myelin. Mutations in P0 have been linked to neuron degeneration and muscle wasting in mice.

Researchers at the University of Buffalo found that when the cell detects defective or misfolded P0 being produced, production of protein is shut off. After the cell has corrected the problem, a protein called Gadd34 causes the cell to resume production of P0. Unfortunately, the Gadd34 causes very high levels of P0 and myelin to be produced, which actually causes more dysfunction in the cell. The excess production of P0 prevents adequate attachment of myelin to the outside of the nerve cell. The researchers found that simply reducing the level of Gadd34 present in the Schwann cells results in increased myelination of the nerve cell. The researchers were able to improve myelin production for nerve cells in both tissue culture and transgenic mouse models.

It will take time and research before this information can be translated into human studies. Researchers will first need to determine if Gadd34 has the same effect on myelin production in human Schwann cells as it does in mouse cells. Because the drug used in tissue culture and in the mouse trials is not approved for human use, the researchers will then need to find or develop a safe molecule that can be given to human volunteers to reduce the level of Gadd34 in the Schwann cells. They will also need to determine the best route of introduction of this molecule. Then, the researchers will need to determine how effectively the rebuilding of the myelin sheath around nerve cells can help restore nerve function. After nerve function is restored, patients would still require physical therapy to help restore muscle function. All of this will take many years to complete, but the prospect of any potential therapy against CMT or other similar neurological diseases is encouraging.

Neuropathies such as CMT are difficult to study, because they may be due to mutations in dozens of genes. The different variations of CMT are also most likely caused by mutations in different genes, and are inherited in different patterns. CMT can be inherited as either a sex-linked disorder or as an autosomal disorder, and can be controlled by either recessive or dominant genes. This diversity of different genetic causes of CMT also means that any potential treatments would need to address all of the potential mutations. One reason Gadd34 is so exciting to researchers is that it could potentially address multiple proteins that are being made incorrectly. Inhibition of Gadd34 could therefore be used to treat multiple types of CMT, as well as other neurothapies.



References:

http://www.sciencedaily.com/releases/201...135037.htm

http://www.ninds.nih.gov/disorders/charc..._tooth.htm
Like Post Reply
#2
It is widely known fact that a large variety of neurodegenerative diseases are caused due to protein misfolding and aggregation as plaques. Diseases like Alzheimer’s , Parkinson’s, Huntington’s, Creutzfeldt- Jacob disease, Gaucher’s disease and even cystic fibrosis are some of the known diseases caused by protein misfolding.

It has been seen that in the majority of protein misfolding disorders, folding is affected due to a mutation causing loss of function, or deleterious gain of function. The former has been observed in cystic fibrosis patients, while the latter is the cause behind Alzheimer’s, Huntington’s etc. Usually molecular chaperones are able to correct the misfolding but in the case of neurodegenerative diseases, molecular chaperones’ functions are blocked and hence natural repair cannot occur. As a result, the misfolded proteins accumulate as fibrous amyloids which when formed in the brain cause lesions.

Research regarding therapeutic mechanism for protein refolding:

Misfolded proteins form a beta sheet structure; hence scientists have been examining the beta folded structure to determine its role in protein misfolding. Beta sheet conformation is formed when protein is oligomerized which can lead to aggregation, loss of biological activity and gain of toxic activity. Scientists have been working on mechanisms to prevent stabilization or oligomerization of the beta sheet. Beta sheet breaker peptides have been used to destabilize the beta sheet’s abnormal structure or to induce its conversion to normal form.

Another mechanism for protein misfolding correction is the use of molecular chaperones. Chemical chaperones have been used to turn back the protein to its natural state. These low molecular mass compounds protect the proteins against denaturation due to heat or chemicals. An example of a chemical chaperone is glycerol which has been used for treatment of cystic fibrosis in case of Delta F08 mutation . Apart from chemical chaperones, pharmacological chaperones have been used for proteopathy studies. Pharmacological chaperones act as ligands which bind to mutant p-glycoprotein that induces aggregation and retention of proteins in the Endoplasmic reticulum. This approach has been tried in case of cancer which is caused by mutations in p53 protein.
Like Post Reply
  

Possibly Related Threads…
Thread
Author
  /  
Last Post



Users browsing this thread:
1 Guest(s)

Potential Mechanism to Refold Proteins in Neurological Disorders00